Main Uses and Therapeutic Role

Alfadiol is a synthetic analog of vitamin D used to address conditions where the body cannot maintain adequate levels of calcium or phosphate due to impaired vitamin D metabolism. Unlike standard vitamin D supplements, Alfadiol is already partially activated, allowing it to bypass certain metabolic steps in the liver or kidneys.

Its primary applications include:

• Chronic Kidney Disease: It is used to manage secondary hyperparathyroidism and bone disease (renal osteodystrophy) in patients with impaired kidney function. In these cases, the kidneys can no longer convert vitamin D into its active form, leading to bone weakening.
• Hypocalcemia: It helps raise and maintain blood calcium levels in patients who have low levels due to various underlying metabolic conditions.
• Hypoparathyroidism: It is used to manage calcium imbalances caused by underactive parathyroid glands, which are responsible for regulating calcium in the blood.
• Vitamin D-Resistant Rickets or Osteomalacia: It is indicated for types of bone softening that do not respond to conventional vitamin D therapy.

Benefits for Bone Health and Metabolism

The therapeutic goal of Alfadiol is to restore the natural balance of minerals required for skeletal integrity and cellular function. By acting as an active vitamin D metabolite, it provides several key physiological benefits:

Regulation of Calcium and Phosphate

Alfadiol facilitates the absorption of calcium and phosphate from the digestive tract into the bloodstream. This ensures that the body has the necessary building blocks for maintaining healthy bone tissue and supporting nerve and muscle function.

Suppression of Parathyroid Hormone (PTH)

In patients with kidney issues or vitamin D deficiencies, the parathyroid glands often become overactive, producing excess PTH. This hormone strips calcium from the bones to compensate for low blood levels. Alfadiol helps suppress the overproduction of PTH, thereby protecting the bones from excessive resorption.

Support of Mineralization

By maintaining appropriate levels of calcium and phosphorus, Alfadiol supports the mineralization of the bone matrix. This process is essential for strengthening the skeleton and preventing the development of deformities, fractures, or bone pain associated with metabolic bone diseases.

Regulatory References

1. World Health Organization Essential Medicines List

Alfadiol's eligibility is strictly determined by regulatory authorities based on a patient's clinical status, mineral balance, and age.

Populations for Whom Use is Defined

Classification	Population/Condition	Regulatory Status
Contraindicated	Patients with existing hypercalcemia, Vitamin D toxicity, metastatic calcification, or hypersensitivity to alfacalcidol [Source 1.1].	Must not use
Conditional Use	Patients with renal impairment, history of kidney stones, or sarcoidosis [Source 1.1].	Use with caution and monitoring
Not Recommended	Pregnant women, breastfeeding mothers, and women of child-bearing potential not using contraception [Source 2.2, 2.4].	Should be avoided
Age-Related	Adults with chronic renal failure or other approved bone/mineral disorders [Source 1.4]. Pediatric use is not authorized or not established in certain regions [Source 3.7].	Restricted by jurisdiction

Eligibility is defined by the necessity of preventing hypercalcemia, as the drug is prohibited when blood calcium is already high. Use in all non-adult populations is restricted or not recommended due to safety concerns or insufficient established data [Source 2.2, 3.7].

Interactions with other medicines and products

The official regulatory interaction profile for Alfadiol is primarily defined by documented effects on mineral homeostasis and systemic drug exposure. The co-administration of Digitalis Glycosides is formally contraindicated if hypercalcaemia is present, as this combination significantly increases the potential for cardiac arrhythmias. Similarly, the concomitant use of other Vitamin D analogues or active metabolites must be avoided due to the enhanced risk of hypercalcaemia.

Several medicinal products are documented to enhance the risk of hypercalcaemia through pharmacodynamic effects. These include Thiazide Diuretics and certain Calcium-containing preparations. In these cases, official labeling specifies that calcium levels must be monitored during co-administration.

Regarding pharmacokinetic effects, Anticonvulsants such as Phenytoin and Carbamazepine are recognized as having enzyme-inducing effects that result in an increased metabolism of Alfacalcidol. Additionally, oral administration with Bile Acid Sequestrants and Mineral Oil may impair intestinal absorption, reducing systemic exposure. To mitigate this absorption interference, regulatory documents mandate that Alfadiol must be administered at least 1 hour before, or 4 to 6 hours after the intake of these specific substances.

Alfadiol also interacts with other ions: the use of Magnesium-containing antacids and Aluminium-containing preparations may be associated with enhanced absorption of these ions, increasing the potential for hypermagnesaemia and aluminium-related toxicities.

How Alfadiol Works

The entire mechanism of Alfadiol is centered on its function as a synthetic precursor to the active hormonal form of Vitamin D, Calcitriol (1,25-dihydroxyvitamin D3), thereby modulating the pathways governing mineral balance through highly specific molecular targets. The active ingredient, Alfacalcidol, is structured to require only a single metabolic activation step. It undergoes a rapid hydroxylation step in the liver, primarily catalyzed by the CYP2R1 enzyme, to yield Calcitriol. This mechanism bypasses the highly regulated 1alpha-hydroxylation step that occurs in the kidneys for native Vitamin D, resulting in the efficient and consistent generation of the active hormone.

Once formed, Calcitriol acts as a powerful agonist for the ubiquitous Vitamin D Receptor (VDR), an intracellular nuclear receptor. The resulting Calcitriol-VDR complex acts as a transcription factor, binding to DNA to initiate the cascade of effects that regulate calcium and phosphate handling. This action increases the synthesis of transport proteins that facilitate absorption of these essential minerals from the intestine and upregulates transport mechanisms that mediate reabsorption in the kidney. Simultaneously, VDR activation on the parathyroid glands effectively suppresses the gene transcription of Parathyroid Hormone (PTH). This action influences the total mineral content and is integral to the drug's effect on calcium and phosphate pathways.

How to use Alfadiol: Official Administration Guidelines

This section outlines the usage patterns for Alfadiol (Alfacalcidol), focusing on the prescribed route, dosage rules, frequency, and special administration conditions.

---

Administration Scope

Parameter	Instruction
Route of administration	Approved for both Oral (capsules or drops) and Intravenous (IV) injection.
Dosing schedule	The initial dose for adults over 20 kg is generally 1 mu g per day. The dosage is not fixed and requires titration via small increments of 0.25 to 0.5 mu g every 2 to 4 weeks based on biochemical response.
Timing in relation to meals (if applicable)	Oral forms can be administered with or without food. If taking a bile acid sequestrant, Alfadiol must be administered at least 1 hour before or 4 to 6 hours after the sequestrant.
Preparation requirements (if applicable)	Oral drop solution must be measured using the integral dropper supplied; IV injection is administered by a healthcare professional.
Age-group administration rules	The starting dose for elderly patients is typically lower at 0.5 mu g/ day. Children under 20 kg generally begin with 0.05 mu g/ kg/ day.
Missed-dose rules	If a dose is missed, it should be taken when remembered, but a double dose must not be taken to compensate.
Special procedural conditions	Intermittent pulsed therapy may be used for patients on dialysis, with doses administered 2 or 3 times per week instead of daily.

---

Instruction Classifications (High-Level)

Classification	Description
Administration method type	Oral / Intravenous
Frequency pattern	Once Daily (Standard) / Intermittent (Pulsed, e.g., 2–3 times per week)
Guideline basis	Standardized medical guidelines
Use-context constraints	Treatment requires regular monitoring of serum calcium, phosphate, and alkaline phosphatase levels.

---

Resulting Procedural Structure

Official step sequence:

• Establish the initial daily dose based on the patient's age and weight, typically 1 mu g for adults.
• Administer the dose via the oral or intravenous route according to the required schedule (daily or intermittent).
• Monitor biochemical parameters regularly during the initial phase to guide necessary dose adjustments.
• Suspend treatment immediately if hypercalcemia occurs, then re-initiate at half the previous dose once calcium levels return to the normal range.

Connection to the overall use protocol

The instructions establish Alfadiol as a monitored, long-term, and actively adjusted therapy. The protocol is defined by a necessary sequence of titration, regular monitoring, and reactive dose adjustment, rather than a static regimen. This structured approach dictates that the duration and maintenance dose are entirely dependent on the patient's continuously observed biochemical response.

Research Evidence / Overview of Studies for Alfadiol

Evidence for use in Kidney-Related Bone and Mineral Disorders

Research has extensively examined Alfadiol in adults with Chronic Kidney Disease (CKD), including patients undergoing maintenance hemodialysis, particularly those where the presence of Secondary Hyperparathyroidism (SHPT) was studied for changes. Multiple Randomized Controlled Trials (RCTs) and long-term observational studies have been conducted. The outcomes studied focused heavily on tracking changes in Parathyroid Hormone (PTH) levels and monitoring serum calcium and phosphate levels (measures of systemic or functional imbalance).

Studies report patterns related to measurements of PTH levels in patients with SHPT. Research also monitors patterns related to calcium and phosphate measurements observed in patient populations with CKD. What remains uncertain is the full characterization of long-term outcomes, such as fracture incidence, from RCTs specifically powered to evaluate these clinical events rather than just biochemical markers.

---

Evidence for use in Hypoparathyroidism, Rickets, and Osteomalacia

The research foundation for Alfadiol's use in Hypoparathyroidism, Rickets, and Osteomalacia is supported by regulatory reviews and data accumulated from well-established clinical use. For Hypoparathyroidism, research examined the need to maintain target serum calcium levels and how researchers monitored symptoms related to neuromuscular hyperexcitability. For Rickets and Osteomalacia, studies explored markers related to bone mineralization and healing.

Studies report patterns related to calcium level measurements for Hypoparathyroidism. For Rickets and Osteomalacia, research highlights changes measured during the study period, such as how skeletal and muscular symptoms evolved in observed populations. The evidence base is primarily historical, meaning modern, prospective, comparative RCTs are limited.

---

Evidence for use in Osteoporosis and Measures of Fall Risk

Alfadiol was studied for use in osteoporosis, mainly in postmenopausal women and older men. The research structure includes meta-analyses of RCTs and dedicated trials which monitored outcomes such as the measured incidence of vertebral and non-vertebral fractures and measurements related to physical performance and the rate of falls.

Meta-analyses described patterns related to the measured incidence of fractures in specific patient subgroups. Research exploring the rate of falls was subject to debate and was not consistently observed across all regulatory assessments. Certainty remains low in some areas because many comprehensive analyses often pool data from trials involving Alfadiol with trials of a similar active compound.

Key Studies & References Alfacalcidol/Calcitriol - Application for inclusion on the WHO Model List of Essential Medicines (EML)

Official Storage and Disposal Requirements

Alfadiol (alfacalcidol) must be stored according to regulatory requirements to maintain its stability. All formulations must be kept out of the sight and reach of children.

Formulation	Required Storage Condition	In-Use Stability
Capsules	Store below 25 °C.	Labeled Shelf-life
Oral Drops	Store in a refrigerator (2 °C to 8 °C); Do not freeze.	Discard 4 months after opening

All forms must be kept in the original container and protected from light and moisture. The medicine must not be stored in a bathroom.

Disposal instructions mandate that unused or expired Alfadiol must not be thrown into household waste or flushed down drains. Disposal must be carried out in accordance with local regulations at a designated pharmaceutical or special waste collection point.